The Blepharitis drugs in development market research report provides comprehensive information on the therapeutics under development for Blepharitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Blepharitis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Blepharitis and features dormant and discontinued products.

GlobalData tracks 18 drugs in development for Blepharitis by 16 companies/universities/institutes. The top development phase for Blepharitis is preclinical with eight drugs in that stage. The Blepharitis pipeline has 18 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Blepharitis pipeline products market are: Azura Ophthalmics, Glaukos and Alcon.

The key targets in the Blepharitis pipeline products market include Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1), Janus Kinase (JAK or EC 2.7.10.2), and IkappaB Kinase (IKK or EC 2.7.11.10).

The key mechanisms of action in the Blepharitis pipeline product include Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist with two drugs in Phase II. The Blepharitis pipeline products include four routes of administration with the top ROA being Ophthalmic and two key molecule types in the Blepharitis pipeline products market including Small Molecule, and Biologic.

Blepharitis overview

Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid’s oil glands, and occasionally allergies. Blepharitis signs and symptoms include red and watery eyes, itchy eyelids, and sensitivity to light. Treatment includes antibiotics, lubricating eye drops, and steroid eye drops or ointments.

For a complete picture of Blepharitis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.